Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

University of Utah Research Foundation

Enata Pharmacueticals, Inc.

Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Abbvie Deutschland Gmbh and Co Kg

Dennie S Welch

Stevan Wakefield Djuric

Wilfried Martin Braje

Sean Colm Turner

Alan Frank Gasiecki

Ana-Lucia Relo

Gang Zhao

Timothy B Towne

Matthew M Ravn

Huanqiu Li

Yat Sun Or

Guoqiang Wang

Andrew J Souers

Yonghua Gai

Philip R Kym

Zhi-Fu Tao

Milan Bruncko

Aaron R Kunzer

Russell Drew Cink

Albert Wayne Kruger

Jorge Gandarilla

Irini Akritopoulou-Zanze

Shashank Shekhar

Min Zhang

Kenneth M Engstrom

Jeff M Kallemeyn

Keith F McDaniel

Xueqing Wang

Gerard M Sullivan

Jennifer M Frost

Xiaohong Song

Andrew S Judd

Kirill A Lukin

David R Hill

Noel S Wilson

Michael J Abrahamson

Hongyu H Zhao

Marvin Robert Leanna

Jianzhang Mei

Richard D Bishop

Westin H Morrill

Christina M Thompson

Matthew J Pelc

Hui-Ju J Chen

Jason P Shanley

Brian E Green

Shuang Chen

Anh P Truong

Erwin R Boghaert

Steven Cramer Cullen

Jonathan A Covel

Carina Cristina Sanchez

Matthew B Kraft

Zhaoming Xiong

Jorge Gandarllla

Yam Poudel

Wei Li

Gary E Keck

Scott L Ackler

Hongyu Zhao

Shashank Shekar

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

Protein tyrosine phosphatase inhibitors and methods of use thereof

The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.

Synthetic route to anti-viral agents

The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R, R, R, R, R, A, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Modulators of 5-HT receptors and methods of use thereof

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Macrocyclic hepatitis C serine protease inhibitors

Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including cancer and Alzheimer's prevention and treatment. The compounds described herein can also treat memory loss. Also described herein are methods for producing macrolactones. The methods permit the high-yield synthesis of macrolactones in fewer steps and with a higher degree of substitution and specificity.

Bryostatin analogues and methods of making and using thereof

Growing community of inventors

Lake Bluff, IL, United States of America

Dennie S Welch